Teva relaunches Depo-Provera generic

JERUSALEM — Teva is reintroducing its generic of Depo-Provera (medroxyprogesterone acetate injectable suspension, 150 mg/mL) contraceptive injection. The drug is indicated to prevent pregnancy.

“This reintroduction brings an additional product to a market that was previously lacking in options,” Teva EVP and president of global generics research and development Dr. Hafrun Fridriksdottir said. “In addition to its importance to patients who will benefit from access to this medicine, this reintroduction holds significant importance to Teva and our generics R&D priorities.”

The reintroduction adds to Teva’s generic injectable business, which the company has been focused on growing. The drug had U.S. sales of approximately $211 million, according to QuintilesIMS data for the 12 months ended July 2017.